Monday, March 25, 2024 11:35:56 PM
5.3. Cell-Directed Extracorporeal Therapy
The Selective Cytopheretic Device (SCD) (SeaStar Medical, Denver, CO, USA), is a technology that sequesters and modulates the most activated neutrophils and monocytes . The SCD is a biocompatible membrane that mimics capillary blood flow and sequesters activated leukocytes. The SCD is utilized in conjunction with CKRT, with the SCD downstream from the CKRT hemofilter in the circuit. The SCD requires the use of regional citrate anticoagulation to induce hypocalcemia within the SCD, which results in both the inhibition of the clotting cascade but also the inactivation of leukocytes. There are a number of smaller studies in critically ill medical patients which have shown promising results, but there are limited data including burn patients . A multicenter randomized controlled trial, NEUTRALIZE-AKI, is currently enrolling critically ill patients with AKI, who require CKRT .
https://www.mdpi.com/2673-1991/5/2/6
Recent ICU News
- SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure • GlobeNewswire Inc. • 04/30/2024 12:30:00 PM
- SeaStar Medical Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 04/17/2024 08:00:00 PM
- SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 • GlobeNewswire Inc. • 03/11/2024 08:05:00 PM
- Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
- FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury • GlobeNewswire Inc. • 02/22/2024 12:53:00 PM
- SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology • GlobeNewswire Inc. • 02/01/2024 01:30:00 PM
- SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market • GlobeNewswire Inc. • 01/26/2024 01:05:00 PM
- SeaStar Medical Appoints David A. Green as Chief Financial Officer • GlobeNewswire Inc. • 01/11/2024 09:05:00 PM
- SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury • GlobeNewswire Inc. • 12/28/2023 01:30:00 PM
- SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts • GlobeNewswire Inc. • 12/13/2023 01:30:00 PM
- SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 11/14/2023 09:04:00 PM
- Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- FDA Issues Approvable Letter for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Patients • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome • GlobeNewswire Inc. • 10/18/2023 12:30:00 PM
- SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023 • GlobeNewswire Inc. • 10/05/2023 12:30:00 PM
- SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption • GlobeNewswire Inc. • 10/03/2023 08:05:00 PM
- FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome • GlobeNewswire Inc. • 09/29/2023 12:30:00 PM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2023 08:35:26 PM
- Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with SeaStar Medical’s Selective Cytopheretic Device Published in the Journal Blood Purification • GlobeNewswire Inc. • 08/29/2023 12:00:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM